Blueprint Medicines Corp Stock
-
Your prediction
Blueprint Medicines Corp Stock
Pros and Cons of Blueprint Medicines Corp in the next few years
Pros
Cons
Performance of Blueprint Medicines Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | - | - | - | - | - | - | - |
| Iovance Biotherapeutics Inc. | -1.640% | 39.741% | 44.943% | -36.413% | 36.235% | -51.347% | -89.243% |
| United Therapeutics | 0.180% | 11.714% | 14.700% | 33.715% | 6.459% | 92.103% | 224.929% |
| Neurocrine Bioscience | 0.990% | 3.013% | -3.559% | 0.725% | -8.972% | 14.383% | 22.330% |
News
Offshore Titans: Transocean Buys Valaris for $5.8B
Transocean Ltd. (NYSE: RIG) has made the definitive move to cement its status as the undisputed leader in offshore drilling. By agreeing to acquire Valaris Limited (NYSE: VAL) in an all-stock
Why Ford's Deal With Amazon Is Bigger Than You Think
Ford Motor Company (NYSE: F) has made a groundbreaking move in automotive retail, announcing a partnership to sell its certified pre-owned (CPO) vehicles directly on Amazon (NASDAQ: AMZN).
This
Time to Take Notice: PEGA’s GenAI Blueprint Delivers Huge Q3 Beat
On a day that saw a handful of highly impressive earnings reports, tech stock Pegasystems (NASDAQ: PEGA) more than held its own. Shares blasted up by 15% on Oct. 22 as the market digested the

